This article has been corrected. Correction in: Oncotarget. 2018; 9:36406.

Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis

Zhun Wang, Shuanghe Peng, Ning Jiang, Aixiang Wang, Shuguang Liu, Hui Xie, Linpei Guo, Qiliang Cai and Yuanjie Niu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:102361-102370. https://doi.org/10.18632/oncotarget.21971

Metrics: PDF 1229 views  |   HTML 2121 views  |   ?  


Zhun Wang1, Shuanghe Peng1, Ning Jiang1, Aixiang Wang1, Shuguang Liu1, Hui Xie1, Linpei Guo1, Qiliang Cai1 and Yuanjie Niu1

1Departments of Urology, Tianjin Institute of Urology, The second Hospital of Tianjin Medical University, Tianjin, 300211, China

Correspondence to:

Yuanjie Niu, email: [email protected]

Keywords: renal cell carcinoma, p53, prognosis, meta-analysis

Received: May 04, 2017     Accepted: September 21, 2017     Published: October 19, 2017


Background: The prognostic value of p53 expression in renal cell carcinoma (RCC) had been investigated in previous studies; however, the results remain inconsistent. This study was performed to investigate the prognostic and clinicopathological significance of p53 protein expression in RCC.

Materials and Methods: Literature was identified from PubMed, Embase, Web of Science, and Cochrane database, which investigated the relationships between p53 expression and outcomes. Hazard ratios (HRs) for survival outcomes and odds ratios (ORs) for clinical parameters associated with p53 were extracted from eligible studies. Heterogeneity was assessed using the I2 value. The fixed-effects model was used if there was no evidence of heterogeneity; otherwise, the random-effects model was used. Publication bias was evaluated using Begg's funnel plots and Egger's regression test.

Results: A total of 2,013 patients from 22 studies were included in the meta-analysis. The results showed that p53 positive expression is associated with poor overall survival (OS) (HR = 2.17, 95% confidence [CI]: 1.51–3.13) and cancer-specific survival (CSS) (HR = 1.59, 95% CI: 1.19–2.12) in RCC. In addition, p53 positive expression was closely correlated with TNM stage (III/IV vs. I/II: OR = 2.51, 95% CI: 1.05–6.00), Fuhrman grade (III/IV vs. I/II: OR = 1.80, 95% CI: 1.24–2.63), and distant metastasis (M1 vs. M0: OR = 1.70, 95% CI: 1.16–2.49), but not related to lymph node involvement (N1 vs. N0: OR = 1.32, 95% CI: 0.80–2.18), primary tumor stage (pT3/pT4 vs. pT1/pT2: OR = 1.16, 95% CI: 0.88–1.53), and sex (n = 2, male vs. female, OR = 1.09, 95% CI: 0.70–1.68).

Conclusions: This study suggests that p53 positive expression is correlated with poor prognosis and advanced clinicopathological features in patients with RCC, which indicates that p53 is a potentially effective therapeutic target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21971